Issues related to FDA drug approval process and therapies for Alzheimer's disease.
2025 · 4th Quarter (Oct 1 - Dec 31)
ALZHEON, INC.
Filed by MILLER STRATEGIES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- Registration
- Posted
- Dec 15, 2025
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- MILLER STRATEGIES, LLC
- Client
- ALZHEON, INC.
- Filing UUID
- ffb789d0-e4be-41b0-ae0c-6dfacdf5abaf
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to FDA drug approval process and therapies for Alzheimer's disease.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.